Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
12 February 2015

Abstract

Take the risk of cardiovascular side effects into account when prescribing tiotropium delivered via Respimat or Handihaler to patients with certain cardiac conditions, who were excluded from clinical trials of tiotropium (including TIOSPIR).